MAPT and Alzheimer disease: The 2024 Alzheimer Association workgroup guidelines for the diagnosis and staging of AD attempt to address this issue by providing a framework that first asks clinicians to separately stage individuals biologically based on tau burden and clinically based on their level of impairment. Once individuals are staged in each dimension, the clinical and biological stage can be compared for congruence (termed canonical) or mismatch with either biological stage greater than clinical stage (termed resilient) or clinical stage greater than biological stage (termed vulnerable).